BRAF mutations are reported in 1-4% of NSCLC diagnoses. Additionally, the common BRAF V600E mutation occurs in around 55% of BRAF-mutant NSCLC. Increased efficacy of BRAF inhibitors along with phenotypic differences from other common mutations in NSCLC, such as EGFR, has placed increased importance on BRAF mutational status (Therapeutic Advancements in Medical Oncology (2017) 9(1): 46-58). BRAFV600E-mutant NSCLC is more commonly seen in adenocarcinoma and �never smokers� and has been associated with poor outcomes and reduced response to platinum-based chemotherapeutic agents. While there have been positive results from treating BRAFV600E-mutant NSCLC with targeted inhibitors, randomized controlled trials are needed to more clearly determine their efficacy (The Lancet Oncology (2016) 17(5): 642-50).